Replies to post #79388 on Biotech Values

[DewDiligence]

Factoid re FoB’s from GPha (see bold-faced text):

http://finance.yahoo.com/news/GPhA-Statement-on-FTC-Report-prnews-15491198.html

We can no longer have a health care system where patients only have access to expensive brand biologic medicines, which some expect to comprise half of all the new medicines approved by FDA in 2012. The price of these drugs continues to soar, placing them out of reach of countless Americans. Brand biologics are simply of no use to patients if they can't afford them. And they are also placing an enormous financial burden on our federal government. The federal government through Medicare Part B spent more for EPO in 2007 than FDA had for its entire FY2008 budget. As the FTC report clearly states, biogenerics 'if brought to market, could reduce the estimated $40.3 billion a year consumers spend on biologic drugs.'